[0005] Elacestrant (RAD1901) is a novel, orally bioavailable SERD. Preclinical data have demonstrated elacestrant, as a single agent and in combination with a CDK4/6 inhibitor, is effective in inhibiting tumor growth in models of ER+ breast cancer with both wild-type and mutant ESR1. Elacestrant monotherapy demonstrated antitumor activity in patient-derived xenograft models of ER+ breast cancer, including those that were insensitive to fulvestrant, estrogen-independent, and/or harbored ESR1 gene mutations. In multiple xenograft models of ER+ breast cancer, the combination of elacestrant with a CDK4/6 inhibitor showed anti-tumor activity that was greater than that observed with either drug alone.

BRIEF DESCRIPTION OF THE FIGURES

[0006] **Figure 1** is a schematic diagram of a study design disclosed herein.

SUMMARY

[0007] In one aspect, the present disclosure relates to the use of ~~a therapeutic combination comprising~~ elacestrant, or a pharmaceutically acceptable salt thereof, ~~and abemaciclib, or a pharmaceutically acceptable salt thereof~~ in the manufacture of a medicament for treating ER+, HER2- breast cancer in a patient; wherein the medicament is to be administered simultaneously, separately or sequentially with abemaciclib, or a pharmaceutically acceptable salt thereof.

[0007a] In one example, the disclosure relates to a method of treating breast cancer in a patient, comprising administering to the patient a therapeutic combination comprising elacestrant, or a pharmaceutically acceptable salt thereof, and abemaciclib, or a pharmaceutically acceptable salt thereof.

[0008] In one example of this example, the patient experiences a greater Progression Free Survival time as compared to a patient who was administered a combination of letrozole and abemaciclib, a combination of anastrozole and abemaciclib, or a combination of fulvestrant and abemaciclib.

[0009] In another example of this example, the patient experiences a greater Progression Free Survival time as compared to a patient who was administered abemaciclib as a monotherapy.

DETAILED DESCRIPTION OF THE INVENTION

[0010] As used herein, RAD1901 or "elacestrant" has the following structure:

WHAT IS CLAIMED IS:

1. Use of ~~a therapeutic combination comprising~~ elacestrant, or a pharmaceutically acceptable salt thereof~~, and abemaciclib, or a pharmaceutically acceptable salt thereof~~ in the manufacture of a medicament for treating ER+, HER2- breast cancer in a patient; wherein the medicament is to be administered simultaneously, separately or sequentially with abemaciclib, or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the patient is a postmenopausal women.

3. The use of claim 1, wherein the patient has not received prior therapy with a CDK4/6 inhibitor or a Selective Estrogen Receptor Degrader (SERD).

4. The use of claim 1, wherein the breast cancer in the patient has progressed on prior endocrine therapy.

~~5. The use of claim 1, wherein the breast cancer in the patient is ER+ breast cancer.~~

~~6. The use of claim 5, wherein the breast cancer in the patient is HER2- breast cancer.~~

~~7.~~5. The use of claim 1, wherein the breast cancer in the patient is advanced or metastatic breast cancer.

~~8.~~6. The use of claim 1, wherein the elacestrant is to be administered to the patient at a dose of from 200-500 mg/day.

~~9.~~7. The use of claim ~~8~~6, wherein the elacestrant is to be administered to the patient at a dose of from 250-450 mg/day.

~~10.~~8. The use of claim ~~9~~7, wherein the elacestrant is to be administered to the patient at a dose of about 300 mg/day.

~~11.~~9. The use of claim ~~10~~8, wherein the elacestrant is to be administered to the patient at a dose of about 300 mg/day, in one administration per day.

~~12.~~10. The use of claim ~~9~~7, wherein the elacestrant is to be administered to the patient at a dose of about 400 mg/day.

~~13.~~11. The use of claim ~~12~~10, wherein the elacestrant is to be administered to the patient at a dose of about 400 mg/day, in one administration per day.

~~14.~~12. The use of claim 1, wherein the abemaciclib is to be administered to the patient at a dose of from 150-400 mg/day.

~~15.~~13. The use of claim ~~14~~12, wherein the abemaciclib is to be administered to the patient at a dose of about 200 mg/day.

~~16.~~14. The use of claim ~~15~~13, wherein the abemaciclib is to be administered to the patient at a dose of about 200 mg/day, in two administrations per day.

~~17.~~15. The use of claim ~~16~~14, wherein the abemaciclib is to be administered to the patient at a dose of about 100 mg twice per day.

~~18.~~16. The use of claim ~~14~~12, wherein the abemaciclib is to be administered to the patient at a dose of about 300 mg/day.

~~19.~~17. The use of claim ~~18~~16, wherein the abemaciclib is to be administered to the patient at a dose of about 300 mg/day, in two administrations per day.

~~20.~~18. The use of claim ~~19~~17, wherein the abemaciclib is to be administered to the patient at a dose of about 150 mg twice per day.

~~21.~~19. The use of claim 1, wherein the elacestrant is to be administered to the patient at a dose of about 400 mg/day, and the abemaciclib is to be administered to the patient at a dose of about 300 mg/day.

~~22.~~20. The use of claim ~~21~~19, wherein the abemaciclib is to be administered to the patient at a dose of 150 mg twice per day.

~~23.~~21. The use of claim 1, wherein the elacestrant is to be administered to the patient at a dose of about 300 mg/day, and the abemaciclib is to be administered to the patient at a dose of about 300 mg/day.

~~24.~~22. The use of claim ~~23~~21, wherein the abemaciclib is to be administered to the patient at a dose of 150 mg twice per day.

~~25.~~23. The use of claim 1, wherein the elacestrant is to be administered to the patient at a dose of about 300 mg/day, and the abemaciclib is to be administered to the patient at a dose of about 200 mg/day.

~~26.~~24. The use of claim ~~25~~23, wherein the abemaciclib is to be administered to the patient at a dose of 100 mg twice per day.

~~27.~~25. The use of claim 1, wherein the elacestrant is to be administered to the patient at a dose that is the maximum tolerated dose for the patient.

~~28.~~26. The use of claim 1, wherein the abemaciclib is to be administered to the patient at a dose that is the maximum tolerated dose for the patient.

~~29.~~27. The use of claim 1, wherein the patient experiences a greater Progression Free Survival time as compared to a patient who was to be administered a combination of letrozole and abemaciclib, a combination of anastrozole and abemaciclib, or a combination of fulvestrant and abemaciclib.

~~30.~~28. The use of claim ~~29~~27, wherein the breast cancer is ER+/HER2- advanced or metastatic breast cancer, and the patient has progressed on or after prior adjuvant or metastatic endocrine therapy, and has not received prior treatment with a CDK4/6 inhibitor or a SERD.

~~31.~~29. The use of claim ~~29~~27, wherein the patient who was to be administered a combination of letrozole and abemaciclib was to be administered 2.5 mg once per day of letrozole and 125 mg twice daily of abemaciclib.

~~32.~~30. The use of claim ~~29~~27, wherein the patient who was to be administered a combination of anastrozole and abemaciclib was to be administered 1 mg once per day of anastrozole and 125 mg twice daily of abemaciclib.

~~33.~~31. The use of claim ~~29~~27, wherein the patient who was to be administered a combination of fulvestrant and abemaciclib was to be administered 500 mg fulvestrant injection as two 5 mL injections intramuscularly into the buttocks (gluteal area), at a rate of 1-2 minutes per injection, one in each buttock, on days 1, 15, and 29 and once monthly thereafter, and 125 mg twice daily of abemaciclib.

~~34.~~32. The use of claim ~~29~~27, wherein the patient experiences a greater Progression Free Survival time as compared to a patient who was to be administered a combination of letrozole and abemaciclib and wherein the breast cancer is ER+/HER2- advanced or metastatic breast cancer, and the patient has not received prior systemic anti-cancer therapies for their advanced/metastatic disease, and has not received prior treatment with a CDK4/6 inhibitor or a SERD.

~~35.~~33. The use of claim ~~34~~32, wherein the patient who was to be administered a combination of letrozole and abemaciclib was to be administered 2.5 mg once per day of letrozole and 125 mg twice daily of abemaciclib.

~~36.~~34. The use of claim 1, wherein the patient experiences a greater Progression Free Survival time as compared to a patient who was to be administered abemaciclib as a monotherapy.

~~37.~~35. The use of claim ~~36~~34, wherein the breast cancer is ER+/HER2- advanced or metastatic breast cancer, and the patient has received prior systemic anti-cancer therapy including ≤ 2 prior chemotherapy for metastatic breast cancer permitted for their advanced or metastatic disease, and wherein the prior systemic anti-cancer therapy did not include a CDK4/6 inhibitor or a SERD.

~~38.~~36. The use of claim ~~36~~34, wherein the patient who was to be administered abemaciclib as a monotherapy was to be administered 200 mg of abemaciclib twice daily.